Most Read Articles
Christina Lau, 06 Sep 2017

In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor significantly reduces bleeding vs triple therapy with warfarin, a P2Y12 inhibitor and aspirin, with comparable rates of thromboembolic events, results of the RE-DUAL PCI trial have shown.

19 Jun 2019
Slideshow: Highlights from the Asian Pacific Society of Cardiology 2019 Congress
2 days ago
A study has recently derived and validated a new index for preoperative cardiovascular evaluation, which can significantly contribute to the efficient triage and management of patients scheduled for noncardiac surgery. The new Cardiovascular Risk Index (CVRI) demonstrates a robust discriminatory power that can effectively stratify patients into low-, intermediate- and high-risk groups.
04 Jun 2019
The addition of alirocumab to intensive statin therapy appears to cut the risk of death following acute coronary syndrome, especially if treatment is sustained for at least 3 years, if baseline low-density lipoprotein cholesterol (LDL-C) is ≥100 mg/dL or if achieved LDL-C is low, according to data from the ODYSSEY OUTCOMES.

Persistent high residual inflammatory risk linked to MACCE in patients undergoing PCI

23 May 2019

Persistent high residual inflammatory risk (RIR) is frequent in patients undergoing percutaneous coronary intervention (PCI) with baseline low-density lipoprotein cholesterol (LDL-C) ≤70 mg/dl and appears to increase the risk of major adverse cardiac and cerebrovascular event (MACCE; ie, death, myocardial infarction or stroke), a recent study has shown.

Of the 3,013 patients included, 1,225 (41.7 percent) had persistent low RIR, 414 (13.7 percent) had attenuated RIR, 346 (11.5 percent) had increased RIR and 1,028 (34.1 percent) had persistent high RIR.

A stepwise increase was seen in the incidence rates of MACCE overall, transitioning from the persistent low to the attenuated, increased and persistent high RIR (64.4 vs 96.6 vs 138.0 vs 152.4 per 1,000 patient-years, respectively; p<0.001).

The robust association between the presence of persistent high RIR and MACCE persisted even after adjustment (adjusted hazard ratio, 2.10; 95 percent CI, 1.45–3.02; p<0.001).

“Targeting residual inflammation in patients with optimal LDL-C control may further improve outcomes after PCI,” the authors said.

This study retrospectively analysed all patients undergoing PCI between January 2009 and December 2016 in a single tertiary centre, with baseline LDL-C ≤70 mg/dl and serial high-sensitivity C-reactive protein (hsCRP) assessments (at least two measurements ≥4 weeks apart).

High RIR was defined as hsCRP >2 mg/l. Patients were categorized as follows: persistent low RIR (first low then low hsCRP); attenuated RIR (first high then low hsCRP); increased RIR (first low then high hsCRP); or persistent high RIR (first high then high hsCRP). MACCE within 1 year of the second hsCRP measurement was the primary endpoint of interest.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 06 Sep 2017

In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor significantly reduces bleeding vs triple therapy with warfarin, a P2Y12 inhibitor and aspirin, with comparable rates of thromboembolic events, results of the RE-DUAL PCI trial have shown.

19 Jun 2019
Slideshow: Highlights from the Asian Pacific Society of Cardiology 2019 Congress
2 days ago
A study has recently derived and validated a new index for preoperative cardiovascular evaluation, which can significantly contribute to the efficient triage and management of patients scheduled for noncardiac surgery. The new Cardiovascular Risk Index (CVRI) demonstrates a robust discriminatory power that can effectively stratify patients into low-, intermediate- and high-risk groups.
04 Jun 2019
The addition of alirocumab to intensive statin therapy appears to cut the risk of death following acute coronary syndrome, especially if treatment is sustained for at least 3 years, if baseline low-density lipoprotein cholesterol (LDL-C) is ≥100 mg/dL or if achieved LDL-C is low, according to data from the ODYSSEY OUTCOMES.